Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APGE Apogee Therapeutics	$37.29 -2.2%	$40.09	$26.20 ▼ $63.50	$1.72B	1.43	614,452 shs	552,735 shs
DYN Dyne Therapeutics	$12.38 -1.0%	$10.46	$6.36 ▼ $47.45	$1.76B	1.08	2.97 million shs	1.93 million shs
IMCR Immunocore	$32.88 -0.5%	$33.60	$23.15 ▼ $39.33	$1.65B	0.77	327,356 shs	180,187 shs
PRTC PureTech Health	$18.84 +7.7%	$18.22	$13.30 ▼ $25.00	$434.62M	1.12	2,709 shs	2,412 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APGE Apogee Therapeutics	0.00%	+5.37%	-4.38%	-8.20%	-15.69%
DYN Dyne Therapeutics	0.00%	+10.93%	+31.70%	+4.65%	-71.79%
IMCR Immunocore	0.00%	+2.85%	-9.20%	+8.26%	-11.06%
PRTC PureTech Health	0.00%	+9.22%	+2.09%	+10.05%	-18.93%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership
APGE Apogee Therapeutics	3.0448 of 5 stars	3.5	3.0	2.2	4.2
DYN Dyne Therapeutics	3.3608 of 5 stars	4.5	1.0	2.5	4.2
IMCR Immunocore	1.9214 of 5 stars	3.3	1.0	2.7	2.5
PRTC PureTech Health	2.7907 of 5 stars	3.8	5.0	2.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APGE Apogee Therapeutics	3.00	Buy	$99.00	165.49% Upside
DYN Dyne Therapeutics	3.00	Buy	$33.80	173.02% Upside
IMCR Immunocore	2.50	Moderate Buy	$58.00	76.40% Upside
PRTC PureTech Health	3.50	Strong Buy	$45.00	138.85% Upside

Current Analyst Ratings Breakdown

Latest PRTC, APGE, IMCR, and DYN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
8/6/2025	DYN Dyne Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $13.00
7/31/2025	DYN Dyne Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$66.00 ➝ $36.00
7/29/2025	DYN Dyne Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$25.00 ➝ $23.00
7/29/2025	DYN Dyne Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$37.00 ➝ $31.00
7/29/2025	DYN Dyne Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$50.00 ➝ $38.00
7/15/2025	DYN Dyne Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$10.00 ➝ $9.00
7/11/2025	DYN Dyne Therapeutics	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform
7/7/2025	APGE Apogee Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/7/2025	APGE Apogee Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$90.00
7/7/2025	APGE Apogee Therapeutics	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$100.00 ➝ $115.00

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	$13.43 per share	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	$4.02 per share	N/A
IMCR Immunocore	$356.15M	4.64	N/A	N/A	$7.73 per share	4.25
PRTC PureTech Health	$4.83M	94.12	$2.50 per share	7.55	$17.04 per share	1.11

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APGE Apogee Therapeutics	-$182.15M	-$4.13	N/A	N/A	N/A	N/A	-34.65%	-32.76%	N/A
DYN Dyne Therapeutics	-$317.42M	-$3.86	N/A	N/A	N/A	N/A	-64.12%	-56.75%	N/A
IMCR Immunocore	-$51.09M	-$0.40	N/A	N/A	N/A	-5.70%	-5.40%	-1.93%	11/5/2025 (Estimated)
PRTC PureTech Health	$27.78M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	8/28/2025 (Estimated)

Latest PRTC, APGE, IMCR, and DYN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APGE Apogee Therapeutics	-$1.03	-$1.13	-$0.10	-$1.13	N/A	N/A
8/7/2025	Q2 2025	IMCR Immunocore	-$0.21	-$0.20	+$0.01	-$0.20	$122.96 million	$130.65 million
7/28/2025	Q2 2025	DYN Dyne Therapeutics	-$0.99	-$0.97	+$0.02	-$0.97	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APGE Apogee Therapeutics	N/A	N/A	N/A	N/A	N/A
DYN Dyne Therapeutics	N/A	N/A	N/A	N/A	N/A
IMCR Immunocore	N/A	N/A	N/A	N/A	N/A
PRTC PureTech Health	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APGE Apogee Therapeutics	N/A	16.36	15.82
DYN Dyne Therapeutics	0.17	16.83	16.83
IMCR Immunocore	1.01	5.89	5.86
PRTC PureTech Health	N/A	9.33	9.33

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APGE Apogee Therapeutics	79.04%
DYN Dyne Therapeutics	96.68%
IMCR Immunocore	84.50%
PRTC PureTech Health	0.04%

Insider Ownership

Company	Insider Ownership
APGE Apogee Therapeutics	42.77%
DYN Dyne Therapeutics	14.14%
IMCR Immunocore	10.40%
PRTC PureTech Health	5.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APGE Apogee Therapeutics	91	46.11 million	26.39 million	Optionable
DYN Dyne Therapeutics	100	142.26 million	122.15 million	Optionable
IMCR Immunocore	320	50.23 million	45.01 million	Optionable
PRTC PureTech Health	100	24.13 million	22.85 million	Not Optionable

PRTC, APGE, IMCR, and DYN Headlines

Recent News About These Companies

PureTech Health (NASDAQ:PRTC) Trading Up 1.4% - Still a Buy?

August 15 at 3:03 AM | marketbeat.com

PureTech Founded Entity Vedanta Biosciences Announces Phase 2 Study of VE202 in Ulcerative Colitis Did Not Meet Primary Endpoint

August 13, 2025 | businesswire.com

PureTech Health plc: PureTech Announces Board Change

July 31, 2025 | finanznachrichten.de

PureTech Health (NASDAQ:PRTC) Shares Down 7.3% - Here's What Happened

July 23, 2025 | marketbeat.com

PureTech CEO Bharatt Chowrira steps down

July 16, 2025 | thepharmaletter.comT

PureTech Health CEO Bharatt Chowrira Resigns

July 16, 2025 | marketwatch.com

PureTech Announces Leadership Transition

July 16, 2025 | businesswire.com

PureTech Health announces board chair Raju Kucherlapati steps down

July 10, 2025 | investing.com

PureTech Health plc (PRTC) Income Statement - Yahoo Finance

July 9, 2025 | finance.yahoo.com

PureTech Announces Board Change

July 8, 2025 | businesswire.com

Why This Biotech Stock Just Doubled In A Single Day

June 26, 2025 | benzinga.com

PureTech’s Deupirfenidone (LYT-100) Demonstrates Strong and Durable Efficacy as a Monotherapy with Favorable Tolerability in Phase 2b ELEVATE IPF Trial

May 22, 2025 | businesswire.com

PureTech’s deupirfenidone shows strong and durable efficacy

May 21, 2025 | thepharmaletter.comT

PureTech Announces Publication of New Research Highlighting Untold Experiences of People Living with Idiopathic Pulmonary Fibrosis (IPF)

May 9, 2025 | businesswire.com

PureTech to Present Results from Phase 2b ELEVATE IPF Trial of Deupirfenidone (LYT-100) at the American Thoracic Society International Conference

May 1, 2025 | finance.yahoo.com

PureTech to Present Results from Phase 2b ELEVATE…

May 1, 2025 | pharmiweb.comP

PureTech Health plc (PRTC) Q4 2024 Earnings Call Transcript

April 30, 2025 | seekingalpha.com

PureTech Announces Annual Results for Year Ended December 31, 2024

April 30, 2025 | businesswire.com

PureTech Health Stock Price, Quotes and Forecasts | NASDAQ:PRTC | Benzinga

April 22, 2025 | benzinga.com

Leerink Partners Keeps Their Buy Rating on PureTech Health (PRTC)

April 10, 2025 | markets.businessinsider.com

PureTech Appoints Peel Hunt as Joint UK Corporate Broker

April 9, 2025 | businesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTC, APGE, IMCR, and DYN Company Descriptions

Apogee Therapeutics NASDAQ:APGE

$37.29 -0.83 (-2.18%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$37.44 +0.15 (+0.40%)

As of 08/15/2025 07:58 PM Eastern

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs comprise APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. Apogee Therapeutics, Inc. was incorporated in 2022 and is headquartered in Waltham, Massachusetts.

Dyne Therapeutics NASDAQ:DYN

$12.38 -0.12 (-0.96%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$12.38 -0.01 (-0.04%)

As of 08/15/2025 05:32 PM Eastern

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

Immunocore NASDAQ:IMCR

$32.88 -0.18 (-0.54%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$32.96 +0.08 (+0.24%)

As of 08/15/2025 04:16 PM Eastern

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.

PureTech Health NASDAQ:PRTC

$18.84 +1.34 (+7.66%)

As of 08/15/2025 03:55 PM Eastern

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time